

PRISM MEDICO AND PHARMACY LIMITED

CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com
Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030.

Date: 09.11.2023

To, Department of Corporate Services, BSE LIMITED P. J. Towers, Dalal Street, Mumbai, Maharashtra-400001. ISIN : INE730E01016 Scrip Code: 512217	To, Listing Department, Metropolitan Stock Exchange of India Limited (MSEI) Vibgyor Towers, 4 th Floor, Plot Number C 62, G - Block, Opposite Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai, Maharashtra-400098. SYMBOL: PRISMMEDI
---	---

Subject: Revision in outcome of Board Meeting held on 08th November, 2023.

Reference: Disclosure under Regulation 30 and 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the captioned subject, it is hereby informed that inadvertently the Balance Sheet and Cash Flow Statement for the half year ended 30th September, 2023 could not be attached with the outcome of Board Meeting held on 08th November, 2023 at 04:00 P.M. and concluded at 05:30 P.M. filed pursuant to Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Therefore, the outcome of Board Meeting is being submitted again. You are requested to kindly take the same on record and oblige.

Thanking You.

Yours Truly,

FOR PRISM MEDICO AND PHARMACY LIMITED

**DAVENDE
R SINGH**

DAVENDER SINGH

DIRECTOR

DIN: 09447213

Digitally signed by DAVENDER SINGH
DN: C=IN, S=Haryana, Phone=+919810316867, e=da2291919ec6888edf718d822af54a7b1f1a1e4a15f32b9, PostalCode=133206, STREET =Yamuna Nagar,
OID.2.5.4.65=699dd1fbc77e12452e47ed1e7981ae4,
SERIALNUMBER=442e4020f6d3ce73e9b251f99b6d9bc75be57fca416d3d58ae70f48c506d, O=Personal, CN=DAVENDER SINGH
Reason: I am the author of this document
Date: 2023.11.09 15:45:05+05'30'
Foxit PDF Reader Version: 2023.2.0



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Standalone Un-Audited Financial Result of **M/s. Prism Medico And Pharmacy Ltd** having its Regd. Office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh - 173030 for the Quarter ended 30th September 2023 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards (' Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.
Chartered Accountants



Date : 08.11.2023

UDIN : 23547759BGROHD9859

PRISM MEDICO AND PHARMACY LIMITED

CIN: L24100HP2002PLC009299; EMAIL ID: INVESTORGRIEVANCEWML@gmail.com
REGISTERED OFFICE: SUKETI ROAD, KALA AMB, SIRMAUR, HIMACHAL PRADESH-173030

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2023 (In Lakhs)

PARTICULARS	Quarter Ended				Year Ended	Year Ended (Audited)	Year Ended (Audited)
	30.09.2023	30.06.2023	30.09.2022	Year to date 30.09.2023	Year to date 30.09.2023	31.03.2023	31.03.2022
I Income							
Revenue from operations	3.27	-	-	3.27	3.27	127.06	844.38
Other income	1.06	1.63	-	2.69	2.69	0.17	0.02
Total income from operations	4.33	1.63	-	5.96	5.96	127.23	844.40
II Expenses							
Cost of material consumed	5.07	-	-	5.07	5.07	114.07	1,055.18
Change in inventories	-	-	-	-	-	-	(192.39)
Employee benefit expenses	0.77	0.51	0.51	1.28	1.28	4.66	19.04
Finance costs	-	0.29	-	0.29	0.29	0.03	0.05
Depreciation and amortization expenses	0.13	0.13	0.33	0.26	0.26	0.66	0.87
Other expenses	3.79	9.60	1.34	13.39	13.39	18.03	11.55
Total expenses	9.76	10.53	2.18	20.29	20.29	137.45	894.29
III Profit/(Loss) before exceptional items and tax	(5.43)	(8.90)	(2.18)	(14.33)	(14.33)	(10.22)	(49.89)
IV Exceptional items	-	-	-	-	-	-	-
V Profit/(Loss) before tax	(5.43)	(8.90)	(2.18)	(14.33)	(14.33)	(10.22)	(49.89)
VI Tax expenses							
a) Current tax	-	-	-	-	-	-	-
b) Deferred tax	-	-	-0.0400	-	-	2.59	12.90
b) Mat Credit	-	-	-	-	-	-	-
VII Net Profit/(Loss) for the period/year	(5.43)	(8.90)	(2.22)	(14.33)	(14.33)	(7.63)	(36.99)
VIII Other comprehensive income (net of tax)							
Items that will not be reclassified to profit or loss:							
obligations	-	-	-	-	-	-	-
ii) Prior period income adjustment (Net of tax)	-	-	-	-	-	-	-
Total other comprehensive income	-	-	-	-	-	-	-
Total comprehensive income for the period/year (VII+VIII)	(5.43)	(8.90)	(2.22)	(14.33)	(14.33)	(7.63)	(36.99)
X Paid-up equity share capital (face value of the share shall be indicated)	606.34	606.34	606.34	606.34	606.34	606.34	606.34
XI Other equity (excluding revaluation reserve)	895.48	900.91	639.17	895.48	895.48	909.81	895.48
XII EPS in Rs. (Face Value of Rs. 10/- each)*							
- Basic	(0.0009)	(0.0015)	(0.0004)	(0.0024)	(0.0024)	(0.0013)	(0.00)
- Diluted	(0.0009)	(0.0015)	(0.0004)	(0.0024)	(0.0024)	(0.0013)	(0.00)

Notes:

- The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 08.11.2023 after being reviewed by the Audit Committee.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company is having single segment in accordance with IND AS 108 "Operating Segments" and therefore segment reporting is not applicable to the company.

**FOR AND ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LIMITED**

**DAVENDER
R SINGH**

**DAVENDER SINGH
DIRECTOR
DIN: 09447213**

Place : Kala Amb, Himachal Pradesh.
Date : 8th November, 2023.

Digitally signed by DAVENDER SINGH
DN: cn=DAVENDER SINGH, o=PRISM MEDICO AND PHARMACY LIMITED, email=DAVENDER.SINGH@PRISM-MEDICO-AND-PHARMACY.LIMITED, c=IN
Reason: I am the author of this document
Date: 2023.11.08 11:36:40 +05'30'
File: PDF Reader Version 2022.0

PRISM MEDICO AND PHARMACY LIMITED

CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmc@gmail.com

Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030

Statement of Assets and Liabilities

For the half year ended on 30th September, 2023 (Amount in Lakhs)

PARTICULARS	30th September, 2023	31st March, 2023
I. ASSETS		
(1) Non - Current Assets		
(a) Property, Plant and Equipment	3.61	3.88
(b) Financial Assets	-	-
(1) Non-Current Investments	-	-
(c) Deffered Tax Asset	21.38	21.38
(2) Current Assets		
(a) Inventories	677.06	677.06
b) Financial Assets		
(1) Cash and Cash Equivalent	7.97	9.57
(2) Short Term Loans and Advances	447.63	351.24
(3) Trade Receivables	365.26	476.09
(c) Other Current Asset	2.10	0.09
TOTAL	1,525.00	1,539.32
II. EQUITY AND LIABILITIES		
(1) Equity:		
(a) Equity Share Capital	606.34	606.34
(b) Other Equity	895.47	909.81
(2) Current Liabilities		
(a) Financial Liabilities		
(1) Trade Payables	3.83	-
(b) Other Current Liabilities	19.37	23.17
TOTAL	1,525.00	1,539.32

FOR AND ON BEHALF OF THE
BOARD

DAVENDER
SINGH

DAVENDER SINGH
DIRECTOR
DIN: 09447213

Place: Kala Amb, Himachal Pradesh.
Date: 8th November, 2023.

Digitally signed by DAVENDER SINGH
DN: cn=Singh, o=Prism Medico and Pharmacy Limited, email=investorgrievancewmc@gmail.com, c=IN
Reason: I am the author of the document
Date: 2023.11.08 17:28:21 +05'30'
Full PDF Reader Version: 2023.2.0

PRISM MEDICO AND PHARMACY LIMITED

CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com

Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030

Cash Flow Statement for the half year ended 30th September, 2023

	Particulars	Period ended 30th September, 2023 Amount (in Lakh)	Period ended 31st March, 2023 Amount (in Lakh)
A.	Cash Flow from Operating Activities:		
	Profit before tax for the year	(14.34)	(10.23)
	Adjustments for :		
	Depreciation and amortization	0.27	0.66
	Change in reserves	-	295.12
	Interest and finance charges	0.01	0.03
	Operating profit before prior period items and working capital change:	(14.06)	285.58
	Prior period items	-	-
	Operating profit before working capital changes	(14.06)	285.58
	Adjustments for:		
	Decrease/(Increase) in receivables	110.83	11.95
	Inventories	-	-
	Other current assets	(2.01)	3.28
	Other current liabilities	(3.81)	21.43
	Increase/(Decrease) in trade payables	3.83	-
	Cash Generated from Operations	94.79	322.23
	Income tax paid	-	26.81
	Net Cash from Operating Activities	94.79	295.43
B.	Cash Flow from Investing Activities:		
	Investments sold	-	-
	Change in loans and advances	(96.39)	(291.33)
	Net Cash (used)/Generated in Investing Activities	(96.39)	(291.33)
C.	Cash Flow from Financing Activities:		
	Interest and other finance costs paid	(0.01)	(0.03)
	Net Cash (Used)/Generated in Financing Activities	(0.01)	(0.03)
	Net Increase in Cash and Cash Equivalents (A)+(B)+(C)	(1.61)	4.06
	Opening Cash and Cash Equivalents	9.57	5.51
	Closing Cash and Cash Equivalents	7.97	9.57

FOR AND ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LIMITED

**DAVENDER
SINGH**

DAVENDER SINGH
DIRECTOR
DIN: 09447213

Digitally signed by DAVENDER SINGH
DN: cn=, o=Prism Medico and Pharmacy Limited, email=investorgrievancewmcl@gmail.com, c=IN, ou=Sirmaur, st=Himachal Pradesh, postalCode=173030, street=Kala Amb, serialNumber=443620208073e9b25199b66bc715b657c0a46c3258a704, c=IN, ou=Prism Medico and Pharmacy Limited, email=investorgrievancewmcl@gmail.com, cn=DAVENDER SINGH
Reason: I am the author of this document
Date: 2023.11.08 17:36:58 +0530
Foxit PDF Reader Version: 2023.2.0

DATE : 8th November 2023.

PLACE : Kala Amb.